1. Home
  2. NTLA vs WINA Comparison

NTLA vs WINA Comparison

Compare NTLA & WINA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • WINA
  • Stock Information
  • Founded
  • NTLA 2014
  • WINA 1988
  • Country
  • NTLA United States
  • WINA United States
  • Employees
  • NTLA N/A
  • WINA N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • WINA Other Specialty Stores
  • Sector
  • NTLA Health Care
  • WINA Consumer Discretionary
  • Exchange
  • NTLA Nasdaq
  • WINA Nasdaq
  • Market Cap
  • NTLA 1.4B
  • WINA 1.4B
  • IPO Year
  • NTLA 2016
  • WINA 1993
  • Fundamental
  • Price
  • NTLA $13.80
  • WINA $399.62
  • Analyst Decision
  • NTLA Buy
  • WINA Strong Buy
  • Analyst Count
  • NTLA 17
  • WINA 1
  • Target Price
  • NTLA $56.63
  • WINA $445.00
  • AVG Volume (30 Days)
  • NTLA 3.1M
  • WINA 18.0K
  • Earning Date
  • NTLA 11-07-2024
  • WINA 10-16-2024
  • Dividend Yield
  • NTLA N/A
  • WINA 0.65%
  • EPS Growth
  • NTLA N/A
  • WINA N/A
  • EPS
  • NTLA N/A
  • WINA 10.93
  • Revenue
  • NTLA $43,086,000.00
  • WINA $81,781,000.00
  • Revenue This Year
  • NTLA $50.73
  • WINA $0.47
  • Revenue Next Year
  • NTLA $8.69
  • WINA $4.86
  • P/E Ratio
  • NTLA N/A
  • WINA $36.17
  • Revenue Growth
  • NTLA N/A
  • WINA N/A
  • 52 Week Low
  • NTLA $12.82
  • WINA $330.25
  • 52 Week High
  • NTLA $34.87
  • WINA $451.30
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 36.15
  • WINA 54.75
  • Support Level
  • NTLA $12.82
  • WINA $386.88
  • Resistance Level
  • NTLA $17.30
  • WINA $403.14
  • Average True Range (ATR)
  • NTLA 1.11
  • WINA 11.50
  • MACD
  • NTLA -0.11
  • WINA -1.16
  • Stochastic Oscillator
  • NTLA 19.56
  • WINA 38.90

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About WINA Winmark Corporation

Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.

Share on Social Networks: